Rheumatologist and Dermatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant (baricitinib), a JAK1/2 inhibitor (I4V-MC-B025)

First published 04/10/2021

Last updated 12/08/2025

EU PAS number:

EUPAS43239

Study

Finalised

Documents

Study protocol

Updated protocol

LY3009104 B025(b) NI PASS Protocol_Redacted.pdf

First published: 17/05/2024

English (493.76 KB - PDF) View document

Study results

Study report

LY3009104 B025 Non-interventional PASS Final Study Report Version 1.pdf

English (3.79 MB - PDF) View document

Other information

Secondary tabs